Wall Street brokerages expect Viveve Medical Inc (NASDAQ:VIVE) to report sales of $4.60 million for the current quarter, Zacks reports. Four analysts have made estimates for Viveve Medical’s earnings, with the highest sales estimate coming in at $4.92 million and the lowest estimate coming in at $4.37 million. Viveve Medical reported sales of $4.07 million in the same quarter last year, which indicates a positive year over year growth rate of 13%. The company is scheduled to announce its next earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Viveve Medical will report full-year sales of $21.61 million for the current fiscal year, with estimates ranging from $20.88 million to $22.17 million. For the next fiscal year, analysts expect that the company will report sales of $32.39 million, with estimates ranging from $29.12 million to $33.95 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Viveve Medical.
Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings results on Thursday, August 9th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.01. The business had revenue of $5.53 million during the quarter, compared to analysts’ expectations of $4.97 million. Viveve Medical had a negative net margin of 239.33% and a negative return on equity of 551.85%.
VIVE traded down $0.17 during midday trading on Tuesday, reaching $3.47. 6,006 shares of the company’s stock were exchanged, compared to its average volume of 227,523. The company has a current ratio of 4.41, a quick ratio of 4.00 and a debt-to-equity ratio of 3.42. The stock has a market cap of $114.62 million, a P/E ratio of -1.73 and a beta of -0.21. Viveve Medical has a 1-year low of $1.60 and a 1-year high of $5.95.
A number of hedge funds have recently bought and sold shares of the business. LMR Partners LLP bought a new stake in shares of Viveve Medical in the 2nd quarter valued at about $112,000. Paloma Partners Management Co bought a new position in Viveve Medical in the second quarter valued at about $268,000. Northern Trust Corp raised its position in Viveve Medical by 43.4% in the first quarter. Northern Trust Corp now owns 252,974 shares of the company’s stock valued at $926,000 after purchasing an additional 76,519 shares during the last quarter. Marshall Wace LLP raised its position in Viveve Medical by 11.0% in the second quarter. Marshall Wace LLP now owns 441,279 shares of the company’s stock valued at $1,200,000 after purchasing an additional 43,842 shares during the last quarter. Finally, BlackRock Inc. raised its position in Viveve Medical by 8.1% in the first quarter. BlackRock Inc. now owns 780,591 shares of the company’s stock valued at $2,857,000 after purchasing an additional 58,256 shares during the last quarter. 61.99% of the stock is owned by institutional investors.
About Viveve Medical
Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.
See Also: Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.